Blog
Validating a Membership Disclosure Metric for Synthetic Health Data
By Lucy Mosquera | Posted On: October 11, 2022 We have just had a paper published in ...
Blog
RWE guidance watch: EUnetHTA’s Direct and Indirect Comparisons guidance
The European Network for Health Technology Assessment (EUnetHTA) recently published two ...
Blog
Aetion’s best practices referenced in ENCePP’s updated Guide on Methodological Standards in Pharmacoepidemiology
On July 1, 2022, the European Network of Centres for Pharmacoepidemiology and ...
Blog
New estimator uses synthetic data generation for more reliable evaluation of re-identification risk in datasets
By Lucy Mosquera and Abhik Das
Blog
Why work at a startup? Because everything you do matters
Several years ago, during a hiring interview for a software engineer position, the ...
Blog
ISPOR Goes Real-World
Regulators, HTAs, and pharma leaders discuss RWE trends with Aetion experts.
Blog
RWE Guidance: NICE’s RWE Framework
This month, the UK’s National Institute for Health and Care Excellence (NICE) released ...
Blog
Utility Metrics for Evaluating Synthetic Data Generation Methods
By Lucy Mosquera and Xi Fang Posted On: April 8, 2022 In order to work with synthetic ...
Blog
Blog post from CHEO Research Institute
By Replica Analytics staff Posted On: March 24th, 2022 This week, the CHEO Research ...
Blog
Synthetic Data Generation for Implementing the HIPAA Expert Determination Method
By Khaled El Emam Posted On: March 1st, 2022 The Expert Determination method is one of ...
Blog
Re-identification–the wrong criterion for synthetic data
By Khaled El Emam Posted On: February 17th, 2022
Blog
Aetion’s comments to FDA on data standards for RWD in drug and biological product submissions
Last week, Aetion submitted a letter to FDA commenting on the Agency’s recent draft ...
Blog
Speaking with Canadian legislators about anonymization
By Replica staff Posted On: February 9th, 2022
Blog
Aetion’s comments to FDA on electronic health records and claims to support regulatory decisions
Last week, Aetion submitted a letter to FDA commenting on the Agency’s recent draft ...
Blog
Understanding propensity score weighting methods
Oftentimes researchers want to compare two medications—an existing medication to a newly ...
Blog
PETs protect privacy and enable data use and sharing for good
By Khaled El Emam Posted On: January 28th, 2022
Blog
Hot off the presses: Replica’s acquisition by Aetion generates coverage
By Replica Analytics staff Posted On: January 24th, 2022
Blog
A 2021 round-up of 10 articles, media and events about Replica and its solutions
By Replica Analytics staff Posted On: January 13th, 2022
Blog
Why we acquired synthetic data pioneer Replica Analytics
The potential for real-world evidence (RWE) to improve patient lives and better protect ...
Blog
What I learned from former FDA leaders during Aetion’s RWE Summit
Aetion hosted our annual RWE Summit in New York last month, and I am still inspired by ...
Blog
8 Really Good Reasons to Work at Replica Analytics
By Replica Analytics staff Posted On: December 22nd, 2021 At Replica Analytics, we’re ...
Blog
Research spotlight: Using RWE to characterize prescription opioid dispensing patterns after surgical abortion
Over 800,000 abortions occur annually in the United States, the majority of which are ...
Blog
Predictions and resolutions for synthetic data
By Dr. Khaled El Emam Posted On: December 21st, 2021
Blog
Discover AI publishes 7 key use cases for synthetic data in the pharmaceutical industry
By Replica Analytics staff Posted On: December 16, 2021